Calcium  ||| S:0 E:8 ||| NNP
and  ||| S:8 E:12 ||| CC
phosphate  ||| S:12 E:22 ||| JJ
changes  ||| S:22 E:30 ||| NNS
after  ||| S:30 E:36 ||| IN
renal  ||| S:36 E:42 ||| JJ
transplantation  ||| S:42 E:58 ||| NN
Hypercalcemia  ||| S:58 E:72 ||| NNP
and  ||| S:72 E:76 ||| CC
hypophosphatemia  ||| S:76 E:93 ||| NNS
are  ||| S:93 E:97 ||| VBP
frequently  ||| S:97 E:108 ||| RB
observed  ||| S:108 E:117 ||| VBN
in  ||| S:117 E:120 ||| IN
recipients  ||| S:120 E:131 ||| NNS
of  ||| S:131 E:134 ||| IN
a  ||| S:134 E:136 ||| DT
kidney  ||| S:136 E:143 ||| NN
transplant  ||| S:143 E:154 ||| NN
( ||| S:154 E:155 ||| -LRB-
KTx ||| S:155 E:158 ||| NNP
) ||| S:158 E:159 ||| -RRB-
.  ||| S:159 E:161 ||| .
Hypercalcemia  ||| S:161 E:175 ||| NNP
has  ||| S:175 E:179 ||| VBZ
been  ||| S:179 E:184 ||| VBN
reported  ||| S:184 E:193 ||| VBN
in  ||| S:193 E:196 ||| IN
up  ||| S:196 E:199 ||| RB
to  ||| S:199 E:202 ||| TO
66 ||| S:202 E:204 ||| CD
%  ||| S:204 E:206 ||| NN
of  ||| S:206 E:209 ||| IN
KTx  ||| S:209 E:213 ||| JJ
patients ||| S:213 E:221 ||| NNS
.  ||| S:221 E:223 ||| .
Many  ||| S:223 E:228 ||| JJ
factors  ||| S:228 E:236 ||| NNS
have  ||| S:236 E:241 ||| VBP
been  ||| S:241 E:246 ||| VBN
suggested  ||| S:246 E:256 ||| VBN
as  ||| S:256 E:259 ||| IN
the  ||| S:259 E:263 ||| DT
putative  ||| S:263 E:272 ||| JJ
causal  ||| S:272 E:279 ||| JJ
factors ||| S:279 E:286 ||| NNS
;  ||| S:286 E:288 ||| :
however ||| S:288 E:295 ||| RB
,  ||| S:295 E:297 ||| ,
the  ||| S:297 E:301 ||| DT
persistence  ||| S:301 E:313 ||| NN
of  ||| S:313 E:316 ||| IN
moderate-severe  ||| S:316 E:332 ||| JJ
secondary  ||| S:332 E:342 ||| JJ
hyperparathyroidism ||| S:342 E:361 ||| NN
,  ||| S:361 E:363 ||| ,
associated  ||| S:363 E:374 ||| VBN
with  ||| S:374 E:379 ||| IN
a  ||| S:379 E:381 ||| DT
change  ||| S:381 E:388 ||| NN
in  ||| S:388 E:391 ||| IN
the  ||| S:391 E:395 ||| DT
set-point  ||| S:395 E:405 ||| JJ
of  ||| S:405 E:408 ||| IN
the  ||| S:408 E:412 ||| DT
Ca-controlled  ||| S:412 E:426 ||| JJ
parathyroid  ||| S:426 E:438 ||| JJ
hormone  ||| S:438 E:446 ||| NN
( ||| S:446 E:447 ||| -LRB-
PTH ||| S:447 E:450 ||| NNP
)  ||| S:450 E:452 ||| -RRB-
secretion ||| S:452 E:461 ||| NN
,  ||| S:461 E:463 ||| ,
is  ||| S:463 E:466 ||| VBZ
considered  ||| S:466 E:477 ||| VBN
to  ||| S:477 E:480 ||| TO
play  ||| S:480 E:485 ||| VB
a  ||| S:485 E:487 ||| DT
prominent  ||| S:487 E:497 ||| JJ
role ||| S:497 E:501 ||| NN
.  ||| S:501 E:503 ||| .
Hypercalcemia  ||| S:503 E:517 ||| NNP
can  ||| S:517 E:521 ||| MD
negatively  ||| S:521 E:532 ||| VB
impact  ||| S:532 E:539 ||| NN
on  ||| S:539 E:542 ||| IN
both  ||| S:542 E:547 ||| PDT
the  ||| S:547 E:551 ||| DT
graft  ||| S:551 E:557 ||| NN
and  ||| S:557 E:561 ||| CC
patient  ||| S:561 E:569 ||| JJ
outcome ||| S:569 E:576 ||| NN
,  ||| S:576 E:578 ||| ,
increasing  ||| S:578 E:589 ||| VBG
the  ||| S:589 E:593 ||| DT
incidence  ||| S:593 E:603 ||| NN
of  ||| S:603 E:606 ||| IN
nephrocalcinosis ||| S:606 E:622 ||| NN
,  ||| S:622 E:624 ||| ,
which  ||| S:624 E:630 ||| WDT
can  ||| S:630 E:634 ||| MD
induce  ||| S:634 E:641 ||| VB
a  ||| S:641 E:643 ||| DT
worse  ||| S:643 E:649 ||| JJR
graft  ||| S:649 E:655 ||| JJ
outcome ||| S:655 E:662 ||| NN
,  ||| S:662 E:664 ||| ,
inducing  ||| S:664 E:673 ||| VBG
vascular  ||| S:673 E:682 ||| JJ
calcifications ||| S:682 E:696 ||| NN
,  ||| S:696 E:698 ||| ,
and  ||| S:698 E:702 ||| CC
increasing  ||| S:702 E:713 ||| VBG
the  ||| S:713 E:717 ||| DT
incidence  ||| S:717 E:727 ||| NN
of  ||| S:727 E:730 ||| IN
pancreatitis ||| S:730 E:742 ||| NN
.  ||| S:742 E:744 ||| .
In  ||| S:744 E:747 ||| IN
addition ||| S:747 E:755 ||| NN
,  ||| S:755 E:757 ||| ,
severe  ||| S:757 E:764 ||| JJ
hypercalcemia  ||| S:764 E:778 ||| NN
after  ||| S:778 E:784 ||| IN
KTx  ||| S:784 E:788 ||| JJ
often  ||| S:788 E:794 ||| RB
requires  ||| S:794 E:803 ||| VBZ
parathyroidectomy ||| S:803 E:820 ||| VBN
,  ||| S:820 E:822 ||| ,
which  ||| S:822 E:828 ||| WDT
is  ||| S:828 E:831 ||| VBZ
not  ||| S:831 E:835 ||| RB
universally  ||| S:835 E:847 ||| RB
considered  ||| S:847 E:858 ||| VBN
a  ||| S:858 E:860 ||| DT
safe  ||| S:860 E:865 ||| JJ
medical  ||| S:865 E:873 ||| JJ
solution  ||| S:873 E:882 ||| NN
in  ||| S:882 E:885 ||| IN
this  ||| S:885 E:890 ||| DT
clinical  ||| S:890 E:899 ||| JJ
setting ||| S:899 E:906 ||| NN
.  ||| S:906 E:908 ||| .
After  ||| S:908 E:914 ||| IN
KTx ||| S:914 E:917 ||| NNP
,  ||| S:917 E:919 ||| ,
phosphate  ||| S:919 E:929 ||| JJ
levels  ||| S:929 E:936 ||| NNS
often  ||| S:936 E:942 ||| RB
fall  ||| S:942 E:947 ||| VB
below  ||| S:947 E:953 ||| IN
the  ||| S:953 E:957 ||| DT
normal  ||| S:957 E:964 ||| JJ
range ||| S:964 E:969 ||| NN
,  ||| S:969 E:971 ||| ,
with  ||| S:971 E:976 ||| IN
hypophosphatemia  ||| S:976 E:993 ||| NNS
being  ||| S:993 E:999 ||| VBG
observed  ||| S:999 E:1008 ||| VBN
in  ||| S:1008 E:1011 ||| IN
up  ||| S:1011 E:1014 ||| RB
to  ||| S:1014 E:1017 ||| TO
40 ||| S:1017 E:1019 ||| CD
%  ||| S:1019 E:1021 ||| NN
of  ||| S:1021 E:1024 ||| IN
patients ||| S:1024 E:1032 ||| NNS
.  ||| S:1032 E:1034 ||| .
The  ||| S:1034 E:1038 ||| DT
putative  ||| S:1038 E:1047 ||| JJ
causal  ||| S:1047 E:1054 ||| JJ
factors  ||| S:1054 E:1062 ||| NNS
for  ||| S:1062 E:1066 ||| IN
this  ||| S:1066 E:1071 ||| DT
metabolic  ||| S:1071 E:1081 ||| JJ
alteration  ||| S:1081 E:1092 ||| NNS
are  ||| S:1092 E:1096 ||| VBP
persistent  ||| S:1096 E:1107 ||| JJ
hyperparathyroidism ||| S:1107 E:1126 ||| NN
,  ||| S:1126 E:1128 ||| ,
increased  ||| S:1128 E:1138 ||| VBD
levels  ||| S:1138 E:1145 ||| NNS
of  ||| S:1145 E:1148 ||| IN
FGF-23 ||| S:1148 E:1154 ||| NNP
,  ||| S:1154 E:1156 ||| ,
tubular  ||| S:1156 E:1164 ||| JJ
damage  ||| S:1164 E:1171 ||| NN
secondary  ||| S:1171 E:1181 ||| JJ
to  ||| S:1181 E:1184 ||| TO
the  ||| S:1184 E:1188 ||| DT
immunological  ||| S:1188 E:1202 ||| JJ
effects ||| S:1202 E:1209 ||| NNS
,  ||| S:1209 E:1211 ||| ,
and  ||| S:1211 E:1215 ||| CC
toxic  ||| S:1215 E:1221 ||| JJ
and  ||| S:1221 E:1225 ||| CC
vascular  ||| S:1225 E:1234 ||| JJ
effectors ||| S:1234 E:1243 ||| NN
.  ||| S:1243 E:1245 ||| .
Hypophosphatemia  ||| S:1245 E:1262 ||| NNP
can  ||| S:1262 E:1266 ||| MD
negatively  ||| S:1266 E:1277 ||| VB
impact  ||| S:1277 E:1284 ||| NN
on  ||| S:1284 E:1287 ||| IN
either  ||| S:1287 E:1294 ||| DT
skeletal  ||| S:1294 E:1303 ||| NN
or  ||| S:1303 E:1306 ||| CC
muscular  ||| S:1306 E:1315 ||| JJ
systems ||| S:1315 E:1322 ||| NNS
,  ||| S:1322 E:1324 ||| ,
contributing  ||| S:1324 E:1337 ||| VBG
to  ||| S:1337 E:1340 ||| TO
the  ||| S:1340 E:1344 ||| DT
increased  ||| S:1344 E:1354 ||| JJ
incidence  ||| S:1354 E:1364 ||| NN
of  ||| S:1364 E:1367 ||| IN
bone  ||| S:1367 E:1372 ||| NN
fractures  ||| S:1372 E:1382 ||| NN
in  ||| S:1382 E:1385 ||| IN
KTx  ||| S:1385 E:1389 ||| JJ
patients ||| S:1389 E:1397 ||| NNS
.  ||| S:1397 E:1399 ||| .
The  ||| S:1399 E:1403 ||| DT
current  ||| S:1403 E:1411 ||| JJ
therapeutic  ||| S:1411 E:1423 ||| JJ
options  ||| S:1423 E:1431 ||| NNS
should  ||| S:1431 E:1438 ||| MD
take  ||| S:1438 E:1443 ||| VB
into  ||| S:1443 E:1448 ||| IN
account  ||| S:1448 E:1456 ||| NN
an  ||| S:1456 E:1459 ||| DT
accurate  ||| S:1459 E:1468 ||| JJ
pretransplant  ||| S:1468 E:1482 ||| JJ
treatment  ||| S:1482 E:1492 ||| NN
and  ||| S:1492 E:1496 ||| CC
screening  ||| S:1496 E:1506 ||| NN
of  ||| S:1506 E:1509 ||| IN
the  ||| S:1509 E:1513 ||| DT
waiting-list  ||| S:1513 E:1526 ||| JJ
patient  ||| S:1526 E:1534 ||| NN
and  ||| S:1534 E:1538 ||| CC
should  ||| S:1538 E:1545 ||| MD
also  ||| S:1545 E:1550 ||| RB
evaluate  ||| S:1550 E:1559 ||| VB
the  ||| S:1559 E:1563 ||| DT
efficacy  ||| S:1563 E:1572 ||| NN
and  ||| S:1572 E:1576 ||| CC
safety  ||| S:1576 E:1583 ||| NN
profile  ||| S:1583 E:1591 ||| NN
of  ||| S:1591 E:1594 ||| IN
the  ||| S:1594 E:1598 ||| DT
new  ||| S:1598 E:1602 ||| JJ
pharmacological  ||| S:1602 E:1618 ||| JJ
tools  ||| S:1618 E:1624 ||| NNS
( ||| S:1624 E:1625 ||| -LRB-
calcimimetics ||| S:1625 E:1638 ||| LS
)  ||| S:1638 E:1640 ||| -RRB-
in  ||| S:1640 E:1643 ||| IN
comparison  ||| S:1643 E:1654 ||| NN
with  ||| S:1654 E:1659 ||| IN
the  ||| S:1659 E:1663 ||| DT
classical  ||| S:1663 E:1673 ||| JJ
surgical  ||| S:1673 E:1682 ||| JJ
approach  ||| S:1682 E:1691 ||| NN
( ||| S:1691 E:1692 ||| -LRB-
parathyroidectomy ||| S:1692 E:1709 ||| LS
) ||| S:1709 E:1710 ||| -RRB-
.  ||| S:1710 E:1712 ||| .
